These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10981130)

  • 1. Antihypertensive drugs and reversing of endothelial dysfunction in hypertension.
    Taddei S; Virdis A; Ghiadoni L; Sudano I; Salvetti A
    Curr Hypertens Rep; 2000 Feb; 2(1):64-70. PubMed ID: 10981130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.
    Taddei S; Virdis A; Ghiadoni L; Sudano I; Salvetti A
    Drugs; 2002; 62(2):265-84. PubMed ID: 11817973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antihypertensive treatment on endothelial function.
    Virdis A; Ghiadoni L; Taddei S
    Curr Hypertens Rep; 2011 Aug; 13(4):276-81. PubMed ID: 21499710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial factors and microvascular hypertensive disease.
    Rizzoni D; Agabiti-Rosei E
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S15-8. PubMed ID: 11811369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effect of antihypertensive drugs on conduit artery endothelial function.
    Ghiadoni L; Magagna A; Versari D; Kardasz I; Huang Y; Taddei S; Salvetti A
    Hypertension; 2003 Jun; 41(6):1281-6. PubMed ID: 12719441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study.
    Higashi Y; Sasaki S; Nakagawa K; Ueda T; Yoshimizu A; Kurisu S; Matsuura H; Kajiyama G; Oshima T
    J Am Coll Cardiol; 2000 Feb; 35(2):284-91. PubMed ID: 10676671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different effects of antihypertensive drugs on endothelial dysfunction.
    Puddu P; Puddu GM; Cravero E; Muscari A
    Acta Cardiol; 2004 Oct; 59(5):555-64. PubMed ID: 15529563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular remodeling and endothelial function in hypertensive patients: effects of antihypertensive therapy.
    Schiffrin EL
    Scand Cardiovasc J Suppl; 1998; 47():15-21. PubMed ID: 9540129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N; Lim PO; MacDonald TM
    Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients.
    Taddei S; Virdis A; Ghiadoni L; Magagna A; Pasini AF; Garbin U; Cominacini L; Salvetti A
    J Hypertens; 2001 Aug; 19(8):1379-86. PubMed ID: 11518845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension.
    Taddei S; Virdis A; Ghiadoni L; Magagna A; Favilla S; Pompella A; Salvetti A
    Hypertension; 2001 Mar; 37(3):943-8. PubMed ID: 11244022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension.
    On YK; Kim CH; Oh BH; Lee MM; Park YB
    Hypertens Res; 2002 May; 25(3):365-71. PubMed ID: 12135314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy].
    Agabiti-Rosei E
    Drugs; 2003; 63 Spec No 1():19-29. PubMed ID: 12708883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension and endothelial dysfunction: therapeutic approach.
    Ghiadoni L; Taddei S; Virdis A
    Curr Vasc Pharmacol; 2012 Jan; 10(1):42-60. PubMed ID: 22112351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vascular endothelium in hypertension.
    Spieker LE; Flammer AJ; Lüscher TF
    Handb Exp Pharmacol; 2006; (176 Pt 2):249-83. PubMed ID: 16999229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rationale for treatment of endothelial dysfunction in hypertension.
    Ruschitzka F; Corti R; Noll G; Lüscher TF
    J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal vascular protection: a case for combination antihypertensive therapy.
    Vogel RA
    Prev Cardiol; 2006; 9(1):35-41. PubMed ID: 16407701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in pharmacologic modulation of nitric oxide in hypertension.
    Mizuno Y; Jacob RF; Mason RP
    Curr Cardiol Rep; 2010 Nov; 12(6):472-80. PubMed ID: 20809234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension.
    Ghiadoni L; Virdis A; Magagna A; Taddei S; Salvetti A
    Hypertension; 2000 Jan; 35(1 Pt 2):501-6. PubMed ID: 10642349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.